An interventional study of Blood Clot and Platelet Rich Plasma in Revascularization of Immature Permenant Teeth, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
the study concern with the patients who loss the vitality of their teeth before completion of root development and apply new treatment approaches to restore their vitality through different scaffolds applied in inside the root canal and allow growth completion of their immature root
the study assess the regenerative potential of four different biological scaffolds Blood Clot, Platelet rich plasma, Platelet rich fibrin and Collagen membrane as a new treatment modality for non-vital immature permanent incisors
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's enrollment of 40 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For Blood Clot scaffold group, intracanal bleeding was intentionally induced by gently extending a sterile #40 stainless-steel K-file 1-2 mm beyond the apical foramen into the periapical tissues. Bleeding was allowed to reach at least 3 mm below the level of the CEJ, any excess blood above the CEJ coronally was removed with a suitable size of sterile paper points. After waiting nearly 10 minutes, the integrity of the newly formed clot was detected using a suitable sterile paper point
Other: Blood Clot
For PRP group, 5 mL of peripheral venous blood was obtained from the antecubital vein of each patient by venipuncture and collected into a 10 mL sterile glass tube containing acid citrate dextrose as an anticoagulant. The blood sample was initially centrifuged at 2400 rpm for 10 minutes to separate PRP and platelet-poor plasma (PPP) from the erythrocyte fraction. Following the first centrifugation cycle, three distinct layers were observed within the tube.; a bottom red thick layer containing red blood cells, a central buffy lightly yellowish layer containing white blood cells and plasma cells, and a supernatant turbid liquid layer which is acellular plasma. Supernatant layer (PRP + PPP) was carefully transferred to a sterile tube and subjected to a second centrifugation at 3600 rpm for 15 minutes to further separate the PRP from the PPP. After the second centrifugation cycle, PRP precipitated at the bottom of the tube as light yellowish slimy viscous substance which was retri
Other: Platelet Rich Plasma
For PRF group, 5 mL of the own venous blood was collected from the patient arm then was placed in a sterile tube without anticoagulant and centrifuged immediately at 3000 rpm for 10 minutes using a centrifuge machine . Three layers were formed inside each tube: a base layer containing erythrocytes, an intermediate layer of PRF clot, and a surface layer of acellular plasma. The PRF clot was removed from the test tube with sterile cotton plier and then put on a sterile gauze then cleared from the base erythrocyte layer using sterile scissor. The freshly prepared PRF clot was compressed between two sterile gauze pieces to form a membrane. The freshly prepared PRF membrane was sectioned into small fragments using sterile #15 scalpel blade and was placed incrementally inside root canal till the full WL length and nearly up to 3 mm below the level of the CEJ. A sterile hand plugger of appropriate size, adjusted to a length 2-3 mm shorter than the WL, was used to facilitate controlled place
Other: Platelet Rich Fibrin
The collagen membrane scaffold, supplied in a 15 × 20 mm dimension was cut into small pieces using #15 sterile scalpel blade, The resulting collagen fragments were then introduced incrementally into the root canal and gently compacted using the same technique described previously for placement of the PRF scaffold
Other: Collagen Membrane
regenerative endodontic treatment using blood clot as scaffold
regenerative endodontic treatment using platelet rich plasma as scaffold
regenerative endodontic treatment using platelet rich fibrin as scaffold
regenerative endodontic treatment using collagen membrane as scaffold
changing in root length
Time frame: 1 year
changing in periapical lesion size
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Jan 2025, 12 months.
Of 108 non-industry interventional studies with no phase under Thrombosis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 12 months is below that.
Counting every sponsor, half of 115 studies reached it within 24 months; a quarter within 9 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.